Steven R Feldman1, Linda S Cox2, Lindsay C Strowd3, Robert A Gerber4, Steven Faulkner5, Debra Sierka6, Timothy W Smith7, Joseph C Cappelleri8, Mark E Levenberg9. 1. Professor of Dermatology, Pathology, and Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC. 2. Practicing Physician, Adult and Pediatric Allergy and Immunology Practice, and is Assistant Clinical Professor of Medicine, University of Miami School of Medicine and Nova Southeastern University School of Osteopathic Medicine, Ft Lauderdale, FL. 3. Assistant Professor of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC. 4. Senior Director, Outcomes and Evidence, Pfizer, Groton, CT. 5. Medical Outcomes Specialists Team Manager, Pfizer, New York, NY. 6. Director of Medical Affairs, Pfizer, Collegeville, PA, during manuscript development. 7. Director, Real World Data and Analytics, Pfizer, New York, NY. 8. Executive Director of Biostatistics, Pfizer, Groton, CT. 9. Director of US Medical Affairs, Pfizer, Collegeville, PA.
Abstract
BACKGROUND: Atopic dermatitis is a chronic inflammatory skin disease that affects up to 13% of children and 10% of adults in the United States. Among patients and their families, atopic dermatitis has a considerable effect on quality of life and represents a substantial economic burden. OBJECTIVE: To describe the impact and challenges of atopic dermatitis and to provide nondermatologists in the healthcare community an enhanced understanding of atopic dermatitis to facilitate treatment and pharmacy benefit discussions. DISCUSSION: Atopic dermatitis is a heterogeneous disease, and its diagnosis is hampered by a lack of objective diagnostic criteria. The current management guidelines address the distinct clinical phenotypes as a single disease and do not incorporate recent clinical advances, such as the targeting of specific inflammatory processes. The treatment guidelines for atopic dermatitis are complex and challenge healthcare providers, patients, and caregivers. Novel treatments can provide additional therapeutic options for patients with atopic dermatitis. CONCLUSIONS: Treatment options for atopic dermatitis are expanding with the development of novel anti-inflammatory therapies. An increased understanding of these advancements is necessary to optimize care for patients with atopic dermatitis.
BACKGROUND: Atopic dermatitis is a chronic inflammatory skin disease that affects up to 13% of children and 10% of adults in the United States. Among patients and their families, atopic dermatitis has a considerable effect on quality of life and represents a substantial economic burden. OBJECTIVE: To describe the impact and challenges of atopic dermatitis and to provide nondermatologists in the healthcare community an enhanced understanding of atopic dermatitis to facilitate treatment and pharmacy benefit discussions. DISCUSSION: Atopic dermatitis is a heterogeneous disease, and its diagnosis is hampered by a lack of objective diagnostic criteria. The current management guidelines address the distinct clinical phenotypes as a single disease and do not incorporate recent clinical advances, such as the targeting of specific inflammatory processes. The treatment guidelines for atopic dermatitis are complex and challenge healthcare providers, patients, and caregivers. Novel treatments can provide additional therapeutic options for patients with atopic dermatitis. CONCLUSIONS: Treatment options for atopic dermatitis are expanding with the development of novel anti-inflammatory therapies. An increased understanding of these advancements is necessary to optimize care for patients with atopic dermatitis.
Authors: Lawrence F Eichenfield; Anne W Lucky; Mark Boguniewicz; Richard G B Langley; Robert Cherill; Katharine Marshall; Christopher Bush; Michael Graeber Journal: J Am Acad Dermatol Date: 2002-04 Impact factor: 11.527
Authors: Lawrence A Schachner; Cindy Lamerson; Mary P Sheehan; Mark Boguniewicz; Joy Mosser; Sharon Raimer; Toni Shull; Eileen Jaracz Journal: Pediatrics Date: 2005-09 Impact factor: 7.124
Authors: David R Bickers; Henry W Lim; David Margolis; Martin A Weinstock; Clifford Goodman; Eric Faulkner; Ciara Gould; Eric Gemmen; Tim Dall Journal: J Am Acad Dermatol Date: 2006-09 Impact factor: 11.527
Authors: Nicholas Shortt; Alexander Martin; Kyley Kerse; Gabrielle Shortt; Iva Vakalalabure; Luke Barker; Joseph Singer; Bianca Black; Angela Liu; Allie Eathorne; Mark Weatherall; Marius Rademaker; Mike Armour; Richard Beasley; Alex Semprini Journal: EClinicalMedicine Date: 2022-07-15
Authors: Chenlu Zhang; Mahendran Chinnappan; Courtney A Prestwood; Marshall Edwards; Methinee Artami; Bonne M Thompson; Kaitlyn M Eckert; Goncalo Vale; Christos C Zouboulis; Jeffrey G McDonald; Tamia A Harris-Tryon Journal: Proc Natl Acad Sci U S A Date: 2021-09-21 Impact factor: 11.205
Authors: Emma Guttman-Yassky; Andrew Blauvelt; Lawrence F Eichenfield; Amy S Paller; April W Armstrong; Janice Drew; Ramanan Gopalan; Eric L Simpson Journal: JAMA Dermatol Date: 2020-04-01 Impact factor: 10.282
Authors: Heather L Tier; Esther A Balogh; Arjun M Bashyam; Alan B Fleischer; Jonathan M Spergel; E J Masicampo; Lara K Kammrath; Lindsay C Strowd; Steven R Feldman Journal: Dermatol Ther (Heidelb) Date: 2021-02-18
Authors: Stephanie Ghazal; Zainab Ridha; Kathleen D'Aguanno; David Nassim; Andrea Quaiattini; Elena Netchiporouk; Yves Poulin; Sunil Kalia; Danielle Marcoux; Vincent Piguet; Carolyn Jack Journal: Front Med (Lausanne) Date: 2022-03-09
Authors: Jonathan I Silverberg; Eric L Simpson; April W Armstrong; Marjolein S de Bruin-Weller; Alan D Irvine; Kristian Reich Journal: Am J Clin Dermatol Date: 2021-10-26 Impact factor: 7.403